An Insider Mansoor Mirza Unloaded 2000 shares of Karyopharm Therapeutics Inc. (KPTI); Hudbay Minerals Ordinary Shares (canada) (HBM) Sellers Increased By 4.79% Their Shorts

Hudbay Minerals Inc. (NYSE:HBM) Logo

Hudbay Minerals Inc Ordinary Shares (canada) (NYSE:HBM) had an increase of 4.79% in short interest. HBM’s SI was 3.57 million shares in May as released by FINRA. Its up 4.79% from 3.40M shares previously. With 682,800 avg volume, 5 days are for Hudbay Minerals Inc Ordinary Shares (canada) (NYSE:HBM)’s short sellers to cover HBM’s short positions. The SI to Hudbay Minerals Inc Ordinary Shares (canada)’s float is 1.57%. The stock increased 2.74% or $0.2 during the last trading session, reaching $7.5. About 479,509 shares traded. Hudbay Minerals Inc. (NYSE:HBM) has risen 6.02% since May 14, 2017 and is uptrending. It has underperformed by 5.53% the S&P500.

The stock increased 5.70% or $0.97 during the last trading session, reaching $17.98. About 1.34M shares traded or 68.21% up from the average. Karyopharm Therapeutics Inc. (NASDAQ:KPTI) has risen 23.92% since May 14, 2017 and is uptrending. It has outperformed by 12.37% the S&P500.

Mr. Mansoor Mirza, the key director at Karyopharm Therapeutics Inc has lately been connected with a broker trade of 2,000 shares of the public company, valued at $18.0 per share. The transaction was for a total value of of $36,000 US Dollars. The date was 11/05/2018 when Mansoor completed the sale, and it was made public in a 4F filing with the SEC, available on this website.

Since December 11, 2017, it had 0 insider purchases, and 29 sales for $3.19 million activity. Shacham Sharon sold $124,829 worth of stock. Mirza Mansoor Raza had sold 2,000 shares worth $36,000. $124,829 worth of Karyopharm Therapeutics Inc. (NASDAQ:KPTI) shares were sold by Kauffman Michael. Primiano Christopher Brett sold 2,500 shares worth $37,527.

Investors sentiment decreased to 1.56 in Q4 2017. Its down 0.94, from 2.5 in 2017Q3. It dived, as 4 investors sold Karyopharm Therapeutics Inc. shares while 21 reduced holdings. 11 funds opened positions while 28 raised stakes. 30.26 million shares or 8.41% more from 27.91 million shares in 2017Q3 were reported. Tudor Invest Corp Et Al reported 22,836 shares. D E Shaw And Co holds 0% or 72,771 shares in its portfolio. Bnp Paribas Arbitrage Sa accumulated 0% or 7,123 shares. Morgan Stanley has invested 0% in Karyopharm Therapeutics Inc. (NASDAQ:KPTI). Sg Americas Securities Limited Liability stated it has 0% of its portfolio in Karyopharm Therapeutics Inc. (NASDAQ:KPTI). Amundi Pioneer Asset Mgmt has 0% invested in Karyopharm Therapeutics Inc. (NASDAQ:KPTI). Mutual Of America Cap Mngmt Limited Liability Corp holds 0.02% in Karyopharm Therapeutics Inc. (NASDAQ:KPTI) or 155,525 shares. Macquarie Grp Limited has invested 0% in Karyopharm Therapeutics Inc. (NASDAQ:KPTI). Great West Life Assurance Can invested in 1,658 shares or 0% of the stock. Goldman Sachs Grp Inc has 78,107 shares. Thomas J Herzfeld Advsrs has invested 0.01% in Karyopharm Therapeutics Inc. (NASDAQ:KPTI). Point72 Asset Mgmt Lp has invested 0.14% in Karyopharm Therapeutics Inc. (NASDAQ:KPTI). Prudential accumulated 19,130 shares. Ameritas Investment Partners Inc invested in 0% or 2,967 shares. Intll Grp, New York-based fund reported 22,766 shares.

Karyopharm Therapeutics Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of drugs directed against nuclear transport and related targets for the treatment of cancer and other diseases. The company has market cap of $1.08 billion. The Company’s lead drug candidate is Selinexor, which is in Phase IIb clinical trial for patients with heavily pretreated multiple myeloma; Phase Ib/II clinical study in combination with backbone treatments for relapsed/refractory multiple myeloma; Phase II/III clinical trial for patients with relapsed and/or refractory multiple myeloma; Phase II clinical study to treat acute myeloid leukemia; Phase IIb clinical trial for patients with diffuse large B-cell lymphoma; and Phase II/III clinical trial to treat liposarcoma. It currently has negative earnings. The firm is also developing KPT-8602 that is in Phase I/II study for patients with relapsed/refractory multiple myeloma; KPT-9274, which is in Phase I clinical trial for patients with advanced solid malignancies or non-HodgkinÂ’s lymphoma; KPT-335, which is in Phase I clinical trial for the treatment of viral indications; and KPT-350 that is in preclinical stage to treat neurological disorders, and inflammatory and autoimmune diseases.

Among 13 analysts covering Karyopharm Therapeutics Inc. (NASDAQ:KPTI), 12 have Buy rating, 1 Sell and 0 Hold. Therefore 92% are positive. Karyopharm Therapeutics Inc. has $42 highest and $10 lowest target. $24.33’s average target is 35.32% above currents $17.98 stock price. Karyopharm Therapeutics Inc. had 37 analyst reports since August 11, 2015 according to SRatingsIntel. Jefferies maintained the stock with “Buy” rating in Monday, September 11 report. Canaccord Genuity initiated Karyopharm Therapeutics Inc. (NASDAQ:KPTI) on Tuesday, December 22 with “Buy” rating. The firm has “Buy” rating by H.C. Wainwright given on Thursday, August 18. The rating was maintained by MLV on Wednesday, August 12 with “Buy”. The company was maintained on Wednesday, April 25 by Jefferies. The stock has “Overweight” rating by JP Morgan on Wednesday, September 2. The firm earned “Overweight” rating on Tuesday, April 10 by JP Morgan. The firm earned “Overweight” rating on Friday, March 16 by JP Morgan. Canaccord Genuity maintained the stock with “Buy” rating in Tuesday, August 8 report. As per Friday, May 27, the company rating was initiated by Raymond James.

More notable recent Karyopharm Therapeutics Inc. (NASDAQ:KPTI) news were published by: Seekingalpha.com which released: “Karyopharm Impresses In Refractory Multiple Myeloma Trial” on May 01, 2018, also Seekingalpha.com with their article: “Your Daily Pharma Scoop: KPTI Data, Allergan Write-Off, Celgene Down On Delay” published on May 02, 2018, Seekingalpha.com published: “Karyopharm Therapeutics’ (KPTI) CEO Michael Kauffman on Q1 2018 Results – Earnings Call Transcript” on May 10, 2018. More interesting news about Karyopharm Therapeutics Inc. (NASDAQ:KPTI) were released by: Globenewswire.com and their article: “Karyopharm Therapeutics Announces Pricing of Public Offering of Common Stock” published on May 03, 2018 as well as Streetinsider.com‘s news article titled: “After-Hours Stock Movers 04/30: (KPTI) (INGN) (NTRI) Higher; (CGNX) (IVAC) (RIG) Lower (more..)” with publication date: April 30, 2018.

Among 6 analysts covering Hudbay Minerals Inc (NYSE:HBM), 3 have Buy rating, 1 Sell and 2 Hold. Therefore 50% are positive. Hudbay Minerals Inc had 15 analyst reports since July 21, 2015 according to SRatingsIntel. Macquarie Research upgraded Hudbay Minerals Inc. (NYSE:HBM) on Tuesday, March 27 to “Buy” rating. BMO Capital Markets upgraded Hudbay Minerals Inc. (NYSE:HBM) on Thursday, September 29 to “Outperform” rating. The stock of Hudbay Minerals Inc. (NYSE:HBM) earned “Hold” rating by Canaccord Genuity on Thursday, August 6. The rating was upgraded by RBC Capital Markets on Monday, May 16 to “Outperform”. As per Thursday, September 3, the company rating was maintained by Raymond James. The rating was downgraded by BMO Capital Markets on Tuesday, August 2 to “Market Perform”. The stock has “Market Perform” rating by BMO Capital Markets on Monday, October 2. The stock of Hudbay Minerals Inc. (NYSE:HBM) has “Neutral” rating given on Wednesday, April 19 by Credit Suisse. The company was downgraded on Thursday, January 14 by Barclays Capital. Credit Suisse maintained Hudbay Minerals Inc. (NYSE:HBM) rating on Monday, September 11. Credit Suisse has “Neutral” rating and $12 target.

More recent Hudbay Minerals Inc. (NYSE:HBM) news were published by: Seekingalpha.com which released: “Hudbay Minerals’ (HBM) CEO Alan Hair on Q1 2018 Results – Earnings Call Transcript” on May 06, 2018. Also Streetinsider.com published the news titled: “Hudbay Minerals (HBM) Misses Q1 EPS by 2c” on May 02, 2018. Prnewswire.com‘s news article titled: “Recent Developments in the Copper Market” with publication date: May 07, 2018 was also an interesting one.

Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Institutional Positions Chart